Debiopharm’s Post

Great to see our CEO, Michael Pehl, highlighted by Clarivate following the publication of its 'Companies to Watch: Antibody Drug Conjugates' report! https://lnkd.in/dbTeNsct Learn more about Adcendo and our development of first-in-class #ADCs for the treatment of #cancer with a high unmet medical need in the report here: https://lnkd.in/eWhSzAWz #biotech #oncology #lifesciences

Adcendo ApS, aiming to develop breakthrough Antibody Drug Conjugates (ADC) to treat underserved cancers, is one of the seven innovative companies listed in the Clarivate Companies to Watch report this year. The first-in-class (FIC) lead program targets the uPARAP receptor, which is overexpressed by several mesenchymal cancers, including soft tissue sarcoma (STS), bone sarcoma, gastrointestinal stromal tumors (GIST) and mesothelioma.  Why is Adcendo ApS a company to watch? Download the report to discover innovations transforming drug discovery and development, revolutionizing cancer treatment, and capturing big pharma interest, here: https://lnkd.in/g_G6kvm4 #oncology #cancertreatement #biotech #pharma #companiestowatch 

The clinical development of ADCs can be complex. 💡 Antibody-drug conjugates (ADCs) offer a novel approach to targeted #cancer treatment, and are being increasingly used in combination with other agents including as first-line cancer therapies. The FDA has just released comprehensive guidelines for optimising clinical pharmacology studies for ADCs, addressing crucial factors like dosing strategies. 📃 Physiomics plc’s team of dedicated scientists can help companies accelerate the path to success in ADC development. 🚀 Leveraging our expertise in quantitative pharmacology and PK/PD modelling, we offer comprehensive support at every stage, from selecting lead ADC candidates to optimising dosing strategies. Reach out to learn more! #antibodydrugconjugates #drugdevelopment #pharma #biotech #pkpd #qsp #mathematicalmodelling #cancer #oncology #dosing #optimaldose

Adjuvant Protocols of Breast Cancer 🎗️ 4. CMF - There is synergistic action between MTX and 5-FU leading to increase the anti-tumour activity of 5-FU. - Endoxan and 5-FU both compate to bind to the plasma protein may result in defects in the distribution if both of the drugs abd lead to delay the therapeutic effect and even induce toxicity. So the #protocol_order is : F M C #Notes: - MTX is phtotosensetive so must cover the N/S bottle - 5-FU and MTX both are anti- metabolite. - Using leucovorin with this protocol, enhancing the action of 5-FU and reducing the toxicity of MTX #chemotherapy #cancer #oncology #drug #pharmacy #breast_cancer #pharmacist

In a study funded by our division, Meisam Bagheri, Ph.D., Todd Miller, PhD, Diwakar Pattabiraman, et al. found that eribulin (an FDA-approved chemotherapeutic drug) induces chromatin remodeling to reverse epithelial to mesenchymal transition and sensitizes cancer cells to other chemotherapies in preclinical models of triple-negative #BreastCancer. https://lnkd.in/erd5cpTu

They write: Antibody-based targeted therapy in cancer faces a challenge due to uneven antibody distribution in solid tumors, hindering effective drug delivery. We addressed this by developing peptide mimetics with nanomolar-range affinity for Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1) using computational methods. These peptides showed both specific targeting and deep penetration in vitro and in vivo. Additionally, we created peptide-drug conjugates (PDCs) by linking targeting peptides to toxin drugs via various linkers and enhancing their in vivo half-life with fatty side chains for albumin binding. The antitumor candidate II-3 displayed exceptional affinity (KD = 1.72 × 10–9 M), internalization efficiency, anticancer potency (IC50 = 0.015 ± 0.002 μM), and pharmacokinetics (t1/2 = 2.6 h), showcasing a rational approach for designing PDCs with favorable tissue distribution and strong tumor penetration.

Repare Therapeutics has just announced the dosing of the first subject in its Phase I POLAR clinical trial for RP-3467, marking an important step in the fight against solid tumours. As a Polθ ATPase inhibitor, RP-3467 shows great promise, whether used alone or in combination with the PARP inhibitor olaparib. This innovative treatment aims to improve patient outcomes significantly by tackling PARP inhibitor resistance, a major unmet medical need. The POLAR trial will involve 52 participants with various advanced solid tumours, including epithelial ovarian cancer, metastatic breast cancer, prostate cancer, and pancreatic adenocarcinoma. Conducted across multiple centres, this open-label, dose-escalation study will focus on evaluating the safety, pharmacokinetics, pharmacodynamics, and initial clinical activity of RP-3467. The trial's primary goal is to ensure the safety and tolerability of the drug and establish a recommended Phase II dose, especially when used in combination with olaparib 📊 #RepareTherapeutics #LifeSciences #ClinicalTrials #ClinicalResearch #Oncology #Biotechnology #MedicalResearch #StaffingPartner #ElixirAssociates

T-cells recognize foreign matter by using T-cell receptors (TCR) to bind to human leukocyte antigens (HLAs) and work to remove these foreign cells (e.g., virus-infected, malignant, cancerous cells). The promise of T-cell receptor therapy is that you can use this principle to precisely target specific HLAs in a particular disease and perform targeted treatment (for example, hard-to-treat cancers) The problem though is that there are multiple HLAs, even for the same disease amongst different patient populations, resulting in need for libraries of HLAs that every patient with that disease. Thereafter, the treatment needs to be tested to make sure it is safe, validated that it works effectively and manufactured at scale. At #ESMO24, my colleagues presented Anocca's solution: A platform that systematically recreates human T-cell biology to map HLAs, generate therapeutic TCR libraries and manufactures solutions for solid cancers. Here we show data from our lead TCR-T product, KRAS-G12V (a driver in pancreatic, lung and colon cancers) that is advancing to clinical trials. Check out the poster! https://lnkd.in/exUBSvQU

Advancing our diagnostic and therapeutic pipeline:

🌟 Exciting Development in Radiopharmaceuticals 🌟 Curium Pharma has completed enrollment early for its Phase 3 SOLAR-RECUR trial, which evaluates Copper Cu 64 PSMA I&T PET/CT for detecting the biochemical recurrence of prostate cancer. This is a major step forward in advancing diagnostics and theranostics for prostate cancer patients! What's next? ☢️The SOLAR-STAGE trial, focusing on staging high-risk prostate cancer, continues enrolling in the U.S. and will soon expand to Europe. ☢️These efforts aim to improve global PSMA PET imaging access for patients and providers. ☢️Thanks to the patients, healthcare professionals, and clinical teams who made this milestone possible! #NuclearMedicine #ProstateCancer #Radiopharmaceuticals #PSMAPET #ClinicalTrials #Innovation